PBPIA
BOLT icon

Pivotal bioVenture Partners Investment Advisor’s Bolt Biotherapeutics BOLT Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$172K Sell
42,581
-51,992
-55% -$271K 0.06% 13
2025
Q4 		$517K Hold
94,573
– – 0.2% 12
2025
Q3 		$503K Hold
94,573
– – 0.29% 10
2025
Q2 		$546K Hold
94,573
– – 0.34% 12
2025
Q1 		$757K Hold
94,573
– – 0.61% 11
2024
Q4 		$1.02M Hold
94,573
– – 0.69% 9
2024
Q3 		$1.23M Hold
94,573
– – 0.73% 10
2024
Q2 		$1.42M Hold
94,573
– – 1.09% 8
2024
Q1 		$2.65M Hold
94,573
– – 1.7% 8
2023
Q4 		$2.12M Hold
94,573
– – 0.54% 10
2023
Q3 		$1.97M Hold
94,573
– – 0.78% 11
2023
Q2 		$2.42M Hold
94,573
– – 0.8% 10
2023
Q1 		$2.63M Hold
94,573
– – 1.08% 10
2022
Q4 		$2.46M Hold
94,573
– – 1.07% 9
2022
Q3 		$2.8M Hold
94,573
– – 1.02% 10
2022
Q2 		$3.86M Hold
94,573
– – 1.94% 9
2022
Q1 		$5.18M Hold
94,573
– – 2.45% 9
2021
Q4 		$9.27M Hold
94,573
– – 3.88% 9
2021
Q3 		$23.9M Hold
94,573
– – 8.46% 4
2021
Q2 		$29.2M Hold
94,573
– – 11.53% 3
2021
Q1 		$62.2M Buy
+94,573
New +$61.5M 19.97% 2

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Pivotal bioVenture Partners Investment Advisor's BOLT Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor reduced its Bolt Biotherapeutics (BOLT) stake by 55% in Q1 2026, selling an estimated $271K and leaving 42,581 shares worth $172K. The position accounts for 0.06% of the portfolio, ranked #13.

Pivotal bioVenture Partners Investment Advisor first reported a position in BOLT in Q1 2021 and has held it in 21 quarters since. The position peaked at $62.2M in Q1 2021. 24 funds tracked by Wall St. Rank hold BOLT as of Q1 2026.

  • Pivotal bioVenture Partners Investment Advisor held 42,581 shares of Bolt Biotherapeutics worth $172K as of Q1 2026.
  • Pivotal bioVenture Partners Investment Advisor sold 51,992 Bolt Biotherapeutics shares in Q1 2026, an estimated $271K.
  • Bolt Biotherapeutics made up 0.06% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #13 holding.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 21 quarters since.
  • Pivotal bioVenture Partners Investment Advisor's Bolt Biotherapeutics position peaked at $62.2M in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.